# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Lambert syndrome

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-7 of 7 results.
Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Status: Available
Last Changed: May 21, 2018
First Received: Jun 25, 2008
Disease(s): Lambert Eaton Myasthenic Syndrome
Intervention(s): 3, 4 DAP
Locations: University of California, Davis, Sacramento, California, United States
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Status: Available
Last Changed: Jun 13, 2019
First Received: Apr 05, 2013
Disease(s): Lambert Eaton Myasthenic Syndrome
Intervention(s): 3, 4-Diaminopyridine
Locations: University of Colorado, Aurora, Colorado, United States
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Status: Available
Last Changed: May 23, 2018
First Received: Feb 23, 2017
Disease(s): Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
Intervention(s): 3,4-Diaminopyridine
Locations: University of California, Davis Medical Center, Sacramento, California, United States
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Status: Recruiting
Last Changed: Jun 15, 2018
First Received: Apr 01, 2009
Disease(s): Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome
Intervention(s): 3,4-DIAMINOPYRIDINE, 3,4-Diaminopyridine
Locations: Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Status: Available
Last Changed: Apr 21, 2015
First Received: Dec 17, 2013
Disease(s): Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)
Intervention(s): 3,4-diaminopyridine
Locations: Oregon Health & Science University, Portland, Oregon, United States
Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS)
Status: Available
Last Changed: Aug 21, 2019
First Received: Jul 15, 2014
Disease(s): Congenital Myasthenic Syndrome
Intervention(s): Amifampridine Phosphate
Locations: UCLA, Los Angeles, California, United States
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Status: Recruiting
Last Changed: Aug 08, 2019
First Received: Sep 29, 2015
Disease(s): Myasthenic Syndromes, Congenital
Intervention(s): amifampridine phosphate, Placebo
Locations: UCLA Department of Neurology, Los Angeles, California, United States
Johns Hopkins Pediatric Neurology, Baltimore, Maryland, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Ohio State University, Columbus, Ohio, United States